Pharmacokinetics and pharmacodynamics of carboplatin administered in a high-dose combination regimen with thiotepa, cyclophosphamide and peripheral stem cell support

British Journal of Cancer

Volumn 73, Issue 8, 1996, Pages 979-984

  Van Warmerdam, L J C ^a,b   Rodenhuis, S ^a   Van Der Wall, E ^a   Maes, R A A ^c   Beijnen, J H ^a,b,c  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

^b SLOTERVAART HOSPITAL   (Netherlands)

^c UTRECHT UNIVERSITY   (Netherlands)

Author keywords

Carboplatin; High dose chemotherapy; Peripheral stem cell transplantation; Pharmacodynamics; Pharmacokinetics

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CYCLOPHOSPHAMIDE; THIOTEPA;

ADULT; ALOPECIA; ANEMIA; ARTICLE; ASCITES; BREAST CANCER; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; CREATININE CLEARANCE; DIARRHEA; DRUG COMBINATION; DRUG MEGADOSE; DRUG TOXICITY; FEMALE; FEVER; GERM CELL TUMOR; GLOMERULUS FILTRATION RATE; GRANULOCYTOPENIA; HEARING LOSS; HEPATOMEGALY; HOSPITALIZATION; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; MUCOSA INFLAMMATION; NAUSEA; NEPHROTOXICITY; NEUROTOXICITY; NEUTROPENIA; OTOTOXICITY; OVARY CANCER; PHARMACODYNAMICS; PRIORITY JOURNAL; STEM CELL; STEM CELL TRANSPLANTATION; THROMBOCYTOPENIA; VEIN OCCLUSION; VOMITING;

EID: 0029921559     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1996.191     Document Type: Article

References (28)

1. ANTMAN K, AYASH L, ELIAS A, WHEELER C, HUNT M, EDER JP, TEICHER BA, CRITCHLOW J, BIBBO J, SCHNIPPER LE AND FREI E. (1990). A phase II study of high-dose cyclophosphamide, thiotepa, and carboplatin with autologous bonemarrow support in women with measurable advanced breast cancer responding to standard-dose chemotherapy. J. Clin. Oncol., 10, 102-110.
2. CALVERT AH, NEWELL DR, GUMBRELL LA, O'REILLY S, BURNELL M, BOXALL FE, SIDDICK ZH, JUDSON IR AND WILTSHAW E. (1989). Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J. Clin. Oncol., 7, 1748-1756.
3. CHESON BD, LACERNA L, LEYLAND-JONES, SAROSY G AND WITTES RE. (1989). Autologous bone marrow transplantation: current status and future directions. Ann. Intern. Med., 110, 51-65.
4. COCKCROFT DW AND GAULT MH. (1976). Prediction of creatinine clearance from serum creatinine. Nephron., 16, 31-34.
5. ELIAS AD, AYASH LJ, EDER JP, WHEELER C, DEARY J, WEISSMAN L, SCHRYBER S, HUNT M, CRITCHLOW J, SCHNIPPER L, FREI E AND ANTMAN KH. (1991). A phase I study of high-dose ifosfamide and escalating doses of carboplatin with autologous bone marrow support. J. Clin. Oncol., 2, 230-237.
6. nd edition, Marcel Dekker: New York, Basel.
7. JODRELL DI, EGORIN MJ, CANETTA RM, LANGENBERG P, GOLDBLOOM EP, BURROUGHS JN, GOODLOW JL, TAN S AND WILTSHAW E. (1992). Relationships between carboplatin exposure and tumor response and toxicity in patients with ovarian cancer. J. Clin. Oncol., 10, 520-528.
8. MOTZER RJ, SUBHASH CG, TONG WP, MENENDEZ-BOTET C, LYN P, MAZUMDAR M, VLAMIS V, LIN S AND BOSL GJ. (1993). Phase I trial with pharmacokinetic analyses of high-dose carboplatin, etoposide, and cyclophosphamide with autologous bone marrow transplantation in patients with refractory germ cell tumors. Cancer Res., 53, 3730-3735.
9. NEWELL DR, SIDDIK ZH, GUMBRELL LA, BOXALL FE, GORE ME, SMITH IE AND CALVERT AH. (1987). Plasma free pharmacokinetics in patients treated with high dose carboplatin. Eur. J. Cancer Clin. Oncol., 23, 1399-1405.
10. NICHOLS CR, ANDERSEN J, LAZARUS HM, FISHER H, GREER J, STADTMAUER EA, LOEHRER PJ AND TRUMP DL. (1992). High-dose carboplatin and etoposide with autologous bone marrow transplantation in refractory germ cell cancer, an eastern cooperative oncology group protocol. J. Clin. Oncol., 10, 197-201.
11. OZOLS RF, OSTCHEGA Y, CURT G AND YOUNG RC. (1987). High-dose carboplatin in refractory ovarian cancer patients. J. Clin. Oncol., 5, 197-201.
12. POLLERA CF, MAROLLA P, NARDI M, AMEGLIO F, COZZO L AND BEVERE F. (1988). Very high-dose cisplatin-induced ototoxicity: a preliminary report on early and long-term effects. Cancer Chemother. Pharmacol., 21, 61-64.
13. REED E, JANIK J, BOOKMAN MA, ROTHENBERG M, SMITH J, YOUNG RC, OZOLS RF, VANDERMOLEN L, KOHN E, JACOB JL AND CORNELISON TL. (1993). High-dose carboplatin and recombinant granulocyte-macrophage colony-stimulating factor in advanced-stage recurrent ovarian cancer. J. Clin. Oncol., 11, 2118-2126.
14. REYNO LM, EGORIN MJ, CANETTA RM, JODRELL DI, SWENERTON KD, PATER JL, BURROUGHS JN, NOVAK MJ AND SRIDHARA R. (1993). Impact of cyclophosphamide on relationships between carboplatin exposure and response or toxicity when used in the treatment of advanced ovarian cancer. J. Clin. Oncol., 11, 1156-1164.
15. RODENHUIS S, BAARS JW, SCHORNAGEL JH, VLASVELD LT, MANDJES I, PINEDO HM AND RICHEL DJ. (1992). Feasibility and toxicity study of a high-dose chemotherapy regimen for autotransplantation incorporating carboplatin, cyclophosphamide and thiotepa. Ann. Oncol., 3, 855-860.
16. RODENHUIS S, VAN DER WALL E, TEN BOKKEL HUININK WW et al. (1995). Pilot study of a high-dose carboplatin-based salvage strategy for relapsing or refractory germ cell cancer. Cancer Invest. 13 (4), 355-362.
17. SHEA TC, FLAHERTY M, ELIAS A, EDER JP, ANTMAN K, BEGG C, SCHNIPPER L, FREI E AND HENNER WD. (1989). A phase I clinical and pharmacokinetic study of carboplatin and autologous bone marrow support. J. Clin. Oncol., 7, 651-661.
18. SHEA TC, MASON JR, STORNIOLO AM, BISSENT E, BRESLIN M, MULLEN M AND TAETLE R. (1993). High-dose carboplatin chemotherapy with GM-CSF and peripheral blood progenitor cell support, a model for delivering repeated cycles of dose-intensive therapy. Cancer Treat. Rev., 1, 11-20.
19. SIEGERT W, BEYER J, STROHSCHEER I, BAURMANN H, OETTLE H, ZINGSEM J, ZIMMERMANN R, BOKEMEYER C, SCHMOLL HJ AND HUHN D. (1994). High-dose treatment with carboplatin, etoposide, and ifosfamide followed by autologous stem cell transplantation in relapsed or refractory germ cell cancer, a phase I/II study. J. Clin. Oncol., 12, 1223-1231.
20. SØRENSEN BT, STRÖMGREN A, JAKOBSEN P AND JAKOBSEN A. (1993). A limited sampling method for estimation of the carboplatin area under the curve. Cancer Chemother. Pharmacol., 31, 324-327.
21. VAN DER VIJGH WJF. (1991). Clinical pharmacokinetics of carboplatin. Clin. Pharmacokinet., 21, 242-261.
22. VAN DER WALL E, RICHEL DJ, HOLTKAMP MJ, SLAPER-CORTENBACH ICM, VAN DER SCHOOT CE, DALESIO O, NOOIJEN WJ, SCHORNAGEL JH AND RODENHUIS S. (1994). Bone marrow reconstitution after high-dose chemotherapy and autologous peripheral blood progenitor cell, effect of graft size. Ann. Oncol., 5, 795-802.
23. VAN DER WALL E, NOOIJEN WJ, BAARS JW, HOLTKAMP MJ, SCHORNAGEL JH, RICHEL DJ, RUTGERS EJT, SLAPER-CORTENBACH ICM, VAN DER SCHOOT CE AND RODENHUIS S. (1995). High-dose carboplatin, thiotepa and cyclophosphamide (CTC) with peripheral blood stem cell support in the adjuvant therapy of high-risk breast cancer, a practical approach. Br. J. Cancer, 71, 857-862.
24. VAN WARMERDAM LJC, RODENHUIS S, VAN TELLINGEN O, MAAS RAA AND BEIJNEN JH. (1994a). Validation of a limited sampling model for carboplatin in a high dose chemotherapy combination. Cancer Chemother. Pharmacol., 35, 179-181.
25. VAN WARMERDAM LJC, TEN BOKKEL HUINICK WW, MAES RAA AND BEIJNEN JH. (19946). Limited sampling models for anticancer agents. J. Cancer Res. Clin. Oncol., 120, 427-433.
26. VAN WARMERDAM LJC, VAN TELLINGEN O, MAES RAA AND BEIJNEN JH. (1995). A validated method for the analysis of carboplatin using Zeeman atomic absorption spectrometry. Fres. J. Anal. Chem., 351, 777-781.
27. VERMORKEN, J.B, TEN BOKKEL HUININK W.W, EISENHOWER EA, FAVALLI G, BELPOMME D, CONTE PF AND KAYE SB. (1993). Carboplatin versus cisplatin. Ann. Oncol., 4 (suppl.4), S41-S48.
28. WAGSTAFF AJ, WARD A, BENFIELD P AND HEEL RC. (1989). Carboplatin, a preliminary review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the treatment of cancer. Drugs, 37, 162-190.